Edesa Biotech (EDSA) Competitors

Pyxis Oncology (NASDAQ:PYXS) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability.

Do insiders and institutionals hold more shares of PYXS or EDSA?

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 9.8% of Pyxis Oncology shares are owned by company insiders. Comparatively, 22.6% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable earnings and valuation, PYXS or EDSA?

Edesa Biotech has lower revenue, but higher earnings than Pyxis Oncology. Edesa Biotech is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$16.15M	4.20	-$73.79M	-$1.30	-0.85
Edesa Biotech	N/A	N/A	-$6.17M	-$1.87	-1.25

Which has more risk & volatility, PYXS or EDSA?

Pyxis Oncology has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Is PYXS or EDSA more profitable?

Pyxis Oncology's return on equity of -36.22% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-36.22%	-28.76%
Edesa Biotech	N/A	-233.69%	-124.14%

Do analysts prefer PYXS or EDSA?

Pyxis Oncology currently has a consensus target price of $9.20, indicating a potential upside of 736.36%. Edesa Biotech has a consensus target price of $21.00, indicating a potential upside of 801.29%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Edesa Biotech is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Edesa Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer PYXS or EDSA?

Pyxis Oncology received 2 more outperform votes than Edesa Biotech when rated by MarketBeat users. Likewise, 83.33% of users gave Pyxis Oncology an outperform vote while only 77.78% of users gave Edesa Biotech an outperform vote.

Company	Underperform	Outperform
Pyxis Oncology	Outperform Votes 30 83.33%	Underperform Votes 6 16.67%
Edesa Biotech	Outperform Votes 28 77.78%	Underperform Votes 8 22.22%

Does the media refer more to PYXS or EDSA?

In the previous week, Pyxis Oncology and Pyxis Oncology both had 3 articles in the media. Edesa Biotech's average media sentiment score of 0.72 beat Pyxis Oncology's score of 0.36 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pyxis Oncology beats Edesa Biotech on 10 of the 15 factors compared between the two stocks.